Portage Biotech Inc
NASDAQ:ATON
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
InterMetro Communications Inc
OTC:IMTO
|
US |
|
Q
|
Quantum Healthcare Ltd
OTC:QTHLF
|
SG |
|
Inventus Mining Corp
XTSX:IVS
|
CA |
|
I
|
Immutable Holdings Inc
NEO:HOLD
|
CA |
|
W
|
Wasu Media Holding Co Ltd
SZSE:000156
|
CN |
|
FiEE Inc
NASDAQ:FIEE
|
US |
|
S
|
Shenzhen Ruihe Construction Decoration Co Ltd
SZSE:002620
|
CN |
|
Lotus Resources Ltd
OTC:LTSRD
|
AU |
|
Founder's Consultants Holdings Inc
TSE:6542
|
JP |
|
Aspire Biopharma Holdings Inc
NASDAQ:ASBP
|
PR |
Portage Biotech Inc
Goodwill
Portage Biotech Inc
Goodwill Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Goodwill | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Portage Biotech Inc
NASDAQ:ATON
|
Goodwill
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Portage Biotech Inc
Glance View
Portage Biotech, Inc. is a biotechnology company, which engages in the research and development of immuno-oncology therapies for patients with cancer. The firm is engaged in advancing therapies to improve long-term treatment, response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. Its adenosine antagonist platform include PORT-9 and PORT-8. PORT-9 and PORT-8 are in the preclinical stage. Its PORT-8 is a dual inhibitor of adenosine receptors 2A and 2B (A2A/A2B) to address solid tumors. Its PORT-9 is an A2B antagonist designed to treat colorectal and gastrointestinal cancers. Its iNKT Engager platform includes PORT- 3, which is in Phase I.
